Cargando…
Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines
After worldwide implementation of 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10/PCV13), a 20-valent PCV (PCV20) was developed. We assessed dynamics of non-PCV13 additional PCV20 serotypes (VT20–13), compared with all other non-VT20 serotypes, in children <2 years of age in late P...
Autores principales: | , , , , , |
---|---|
Formato: | Online Artículo Texto |
Lenguaje: | English |
Publicado: |
Centers for Disease Control and Prevention
2021
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774550/ https://www.ncbi.nlm.nih.gov/pubmed/33350916 http://dx.doi.org/10.3201/eid2701.201178 |
_version_ | 1783630289596055552 |
---|---|
author | Ben-Shimol, Shalom Givon-Lavi, Noga Kotler, Leore Adriaan van der Beek, Bart Greenberg, David Dagan, Ron |
author_facet | Ben-Shimol, Shalom Givon-Lavi, Noga Kotler, Leore Adriaan van der Beek, Bart Greenberg, David Dagan, Ron |
author_sort | Ben-Shimol, Shalom |
collection | PubMed |
description | After worldwide implementation of 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10/PCV13), a 20-valent PCV (PCV20) was developed. We assessed dynamics of non-PCV13 additional PCV20 serotypes (VT20–13), compared with all other non-VT20 serotypes, in children <2 years of age in late PCV13 (2015–2017) and early PCV (2009–2011) periods. Our prospective population-based multifaceted surveillance included isolates from carriage in healthy children, children requiring chest radiography for lower respiratory tract infections (LRTIs), and children with non-LRTI illness, as well as isolates from acute conjunctivitis, otitis media (OM), and invasive pneumococcal disease (IPD). After PCV13 implementation, VT20–13 increased disproportionally in OM, IPD, and carriage in LRTI. VT20–13/non-VT20 prevalence ratio range was 0.26–1.40. VT20–13 serotypes were more frequently antimicrobial-nonsusceptible than non-VT20 serotypes. The disproportionate increase of VT20–13 in respiratory infections and IPD points to their higher disease potential compared with all other non-VT20 as a group. |
format | Online Article Text |
id | pubmed-7774550 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2021 |
publisher | Centers for Disease Control and Prevention |
record_format | MEDLINE/PubMed |
spelling | pubmed-77745502021-01-01 Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines Ben-Shimol, Shalom Givon-Lavi, Noga Kotler, Leore Adriaan van der Beek, Bart Greenberg, David Dagan, Ron Emerg Infect Dis Research After worldwide implementation of 10-valent and 13-valent pneumococcal conjugate vaccines (PCV10/PCV13), a 20-valent PCV (PCV20) was developed. We assessed dynamics of non-PCV13 additional PCV20 serotypes (VT20–13), compared with all other non-VT20 serotypes, in children <2 years of age in late PCV13 (2015–2017) and early PCV (2009–2011) periods. Our prospective population-based multifaceted surveillance included isolates from carriage in healthy children, children requiring chest radiography for lower respiratory tract infections (LRTIs), and children with non-LRTI illness, as well as isolates from acute conjunctivitis, otitis media (OM), and invasive pneumococcal disease (IPD). After PCV13 implementation, VT20–13 increased disproportionally in OM, IPD, and carriage in LRTI. VT20–13/non-VT20 prevalence ratio range was 0.26–1.40. VT20–13 serotypes were more frequently antimicrobial-nonsusceptible than non-VT20 serotypes. The disproportionate increase of VT20–13 in respiratory infections and IPD points to their higher disease potential compared with all other non-VT20 as a group. Centers for Disease Control and Prevention 2021-01 /pmc/articles/PMC7774550/ /pubmed/33350916 http://dx.doi.org/10.3201/eid2701.201178 Text en https://creativecommons.org/licenses/by/4.0/This is a publication of the U.S. Government. This publication is in the public domain and is therefore without copyright. All text from this work may be reprinted freely. Use of these materials should be properly cited. |
spellingShingle | Research Ben-Shimol, Shalom Givon-Lavi, Noga Kotler, Leore Adriaan van der Beek, Bart Greenberg, David Dagan, Ron Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines |
title | Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines |
title_full | Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines |
title_fullStr | Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines |
title_full_unstemmed | Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines |
title_short | Post–13-Valent Pneumococcal Conjugate Vaccine Dynamics in Young Children of Serotypes Included in Candidate Extended-Spectrum Conjugate Vaccines |
title_sort | post–13-valent pneumococcal conjugate vaccine dynamics in young children of serotypes included in candidate extended-spectrum conjugate vaccines |
topic | Research |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC7774550/ https://www.ncbi.nlm.nih.gov/pubmed/33350916 http://dx.doi.org/10.3201/eid2701.201178 |
work_keys_str_mv | AT benshimolshalom post13valentpneumococcalconjugatevaccinedynamicsinyoungchildrenofserotypesincludedincandidateextendedspectrumconjugatevaccines AT givonlavinoga post13valentpneumococcalconjugatevaccinedynamicsinyoungchildrenofserotypesincludedincandidateextendedspectrumconjugatevaccines AT kotlerleore post13valentpneumococcalconjugatevaccinedynamicsinyoungchildrenofserotypesincludedincandidateextendedspectrumconjugatevaccines AT adriaanvanderbeekbart post13valentpneumococcalconjugatevaccinedynamicsinyoungchildrenofserotypesincludedincandidateextendedspectrumconjugatevaccines AT greenbergdavid post13valentpneumococcalconjugatevaccinedynamicsinyoungchildrenofserotypesincludedincandidateextendedspectrumconjugatevaccines AT daganron post13valentpneumococcalconjugatevaccinedynamicsinyoungchildrenofserotypesincludedincandidateextendedspectrumconjugatevaccines |